Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

This is "a call to action," she said. There are currently three vaccines approved for RSV; two of them -- GSK's Arexvy and Pfizer's Abrysvo -- are protein subunit vaccines, while Moderna's mResvia ...

This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024 ... can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and ...

The U.S. Centers for Disease Control and Prevention’s vaccine panel voted to expand its recommendation for the use of respiratory syncytial virus (RSV) shots in adults 50–59 years of age at ...

With current CDC leadership waiting for Senate confirmation, the Advisory Committee's vaccination recommendations may be approved by Health Secretary Robert F. Kennedy Jr instead. HealthDay News ...

(Reuters) -The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory syncytial virus shots in the second round of their meeting ...